SCHEMBL8073233

SCHEMBL8073233

Cc1ccc(S(=O)(=O)OS(=O)(=O)Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA12 O43570 1/20 0.46
CA3 P07451 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
DNMT1 P26358 1/20 0.45
TLR9 Q9NR96 1/20 0.45
VDR P11473 1/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
G6PD P11413 2/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490 0.86 GAA (0.59) GAACA1CA2CA12CA3
SCHEMBL30862469 0.84 GAA (0.56) GAACA1CA2CA12CA3
Water SCHEMBL3352692 0.84 GAA (0.56) GAACA1CA2CA12CA3
SCHEMBL5314186 0.81 BCHE (0.54) GAACA1CA2CA12CA3
SCHEMBL66115 0.80 GAA (0.52) GAACA1CA2CA12CA3
SCHEMBL2966008 0.80 GAA (0.52) GAACA1CA2CA12CA3
SCHEMBL344977 0.80 GAA (0.52) GAACA1CA2CA12CA3
SCHEMBL526315 0.78 GAA (0.50) GAACA1CA2CA12CA3
SCHEMBL5581695 0.78 GAA (0.50) GAACA1CA2CA12CA3
SCHEMBL3267933 0.78 HTT (0.53) GAACA1CA2CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174930-B2 Preparation of sitagliptin intermediates LEK PHARMACEUTICALS D.D. (SI) 2015-11-03 US claimed
US-20140213810-A1 PREPARATION OF SITAGLIPTIN INTERMEDIATES LEK PHARMACEUTICALS D.D. (SI) 2014-07-31 US claimed
EP-2508506-A1 Preparation of sitagliptin intermediates LEK Pharmaceuticals d.d. (SI) 2012-10-10 EP claimed
US-6033826-A POLYHYDROXYSTYRENE DERIVATIVE CONTAINING AN ACETAL OR KETAL GROUP WHICH CAN EASILY BE ELIMINATED IN THE PRESENCE OF AN ACID IN THE MOLECULE AND HAVING A VERY NARROW MOLECULAR WEIGHT DISTRIBUTION GIVES A RESIST MATERIAL WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2000-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213810-A1 PREPARATION OF SITAGLIPTIN INTERMEDIATES DPP4, DPP3, DPP9 GAA 622/4885CA1 3144/4885CA2 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.